Christy Risinger, MD

In this short update, Dr. Christy Risinger says Mounjaro (generic name tirzepatide) is approved for diabetes treatment and also causes weight loss. She says she expects it to be approved specifically for weight loss in the coming months.

1. 0:00 Intro
2. 0:27 What is MOUNJARO
3. 0:55 How does MOUNJARO work
4. 1:33 Does MOUNJARO cause weight gain

• Who is speaking: Clinician, MD

In this three-minute video, Dr. Christy Risinger answers a question she says patients often ask: why oral Rybelsus is talked about so much less than the injectable GLP-1 medications.

1. 0:00 Introduction to Rybelsus
2. 0:17 Rybelsus efficacy limitations
3. 1:30 Future studies and higher doses
4. 1:58 Injectable vs oral administration

• Doses mentioned: 14 mg, 25 mg and 50 mg
• Who is speaking: Clinician, MD

In this short video, Dr. Christy Risinger explains why she is comfortable prescribing compounded semaglutide. She says the public has been given a lot of misinformation, and suggests some of it comes from large drug companies protecting their names and reputations.

1. 0:00 Intro
2. 0:48 Reliable compounding pharmacies
3. 1:29 sterile compounding pharmacies
4. 1:52 no kickbacks
5. 2:33 no additives
6. 3:32 cost
7. 3:48 conclusion

• Prices mentioned: $300 a month
• Who is speaking: Clinician, MD

In this short video, Dr. Christy Risinger explains what it means that the FDA has taken tirzepatide, sold as Zepbound and Mounjaro, off its drug shortage list.

1. 0:01 Introduction
2. 1:54 Cost and insurance
3. 2:25 Dose change
4. 4:32 Cost and insurance

• Prices mentioned: $600 a month
• Who is speaking: Clinician, MD

Dr. Christy Reisinger, who works in obesity medicine, discusses a large study of semaglutide, which she says is sold as Wegovy and also known as Ozempic. According to the video, Novo Nordisk began the study in 2018 and enrolled more than 17,000 patients aged 45 and older.

1. 0:14 The trials
2. 0:46 Dose change
3. 2:00 Wrapping up

• Doses mentioned: 2.4 mg
• Who is speaking: Clinician, MD